Silymarin in the treatment of patients with primary sclerosing cholangitis: An open-label pilot study

被引:25
作者
Angulo, Paul [1 ]
Jorgensen, Roberta A. [1 ]
Kowdley, Kris V. [2 ]
Lindor, Keith D. [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Univ Washington, Sch Med, Div Gastroenterol & Hepatol, Seattle, WA USA
关键词
primary sclerosing cholangitis; silymarin; treatment;
D O I
10.1007/s10620-007-0052-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum alkaline phosphatase activity (1131 +/- 216 vs. 861 +/- 139, P = 0.007), and aspartate aminotransferase (AST) levels (116 +/- 15 vs. 83 +/- 11, P = 0.01) occurred with treatment. Serum bilirubin levels were not significantly affected by the treatment, while serum albumin and the Mayo risk score remained essentially unchanged. Overall, 34% of patients had a positive response to silymarin as defined by >= 50% improvement or normal status in liver tests. The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial.
引用
收藏
页码:1716 / 1720
页数:5
相关论文
共 24 条
[1]   Primary sclerosing cholangitis - Emerging new promising therapies [J].
Angulo, P ;
Lindor, KD .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 31 (04) :271-273
[2]   Primary sclerosing cholangitis [J].
Angulo, P ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (01) :325-332
[3]   Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid [J].
Angulo, P ;
Patel, T ;
Jorgensen, RA ;
Therneau, TM ;
Lindor, KD .
HEPATOLOGY, 2000, 32 (05) :897-900
[4]   Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats [J].
Boigk, G ;
Stroedter, L ;
Herbst, H ;
Waldschmidt, J ;
Riecken, EO ;
Schuppan, D .
HEPATOLOGY, 1997, 26 (03) :643-649
[5]  
BUZZELLI G, 1993, INT J CLIN PHARM TH, V31, P456
[6]   Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin [J].
Dehmlow, C ;
Erhard, J ;
deGroot, H .
HEPATOLOGY, 1996, 23 (04) :749-754
[7]   RANDOMIZED CONTROLLED TRIAL OF SILYMARIN TREATMENT IN PATIENTS WITH CIRRHOSIS OF THE LIVER [J].
FERENCI, P ;
DRAGOSICS, B ;
DITTRICH, H ;
FRANK, H ;
BENDA, L ;
LOCHS, H ;
MERYN, S ;
BASE, W ;
SCHNEIDER, B .
JOURNAL OF HEPATOLOGY, 1989, 9 (01) :105-113
[8]  
Fuchs E. C., 1995, Hepatology, V22, p286A, DOI 10.1016/0270-9139(95)94866-X
[9]   Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis [J].
Graziadei, IW ;
Wiesner, RH ;
Marotta, PJ ;
Porayko, MK ;
Hay, JE ;
Charlton, MR ;
Poterucha, JJ ;
Rosen, CB ;
Gores, GY ;
LaRusso, NF ;
Krom, RAF .
HEPATOLOGY, 1999, 30 (05) :1121-1127
[10]  
Harnois DM, 2001, AM J GASTROENTEROL, V96, P1558